Evidence map›Paper›PMID 39310112›Full record

ArticleTheranostics2024

The heterobivalent (SSTR2/albumin) radioligand [

Martin Ullrich, Robert Wodtke, Florian Brandt, Robert Freudenberg, Jörg Kotzerke, Susan Richter, Klaus Kopka, Jens Pietzsch

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Theranostics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Pharmaceuticals (Basel, Switzerland) · 2026
    Review
  4. Article
  5. Deciphering the Tumor Uptake of Heterobivalent (SSTJournal of medicinal chemistry · 2025
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Martin UllrichHelmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Dresden, Germany.
Robert WodtkeHelmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Dresden, Germany.
Florian BrandtUniversity Hospital Carl Gustav Carus at the Technische Universität Dresden, Klinik und Poliklinik für Nuklearmedizin, Dresden, Germany.
Robert FreudenbergUniversity Hospital Carl Gustav Carus at the Technische Universität Dresden, Klinik und Poliklinik für Nuklearmedizin, Dresden, Germany.
Jörg KotzerkeUniversity Hospital Carl Gustav Carus at the Technische Universität Dresden, Klinik und Poliklinik für Nuklearmedizin, Dresden, Germany.
Susan RichterUniversity Hospital Carl Gustav Carus at the Technische Universität Dresden, Institute of Clinical Chemistry and Laboratory Medicine, Dresden, Germany.
Klaus KopkaHelmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Dresden, Germany.
Jens PietzschHelmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Dresden, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Somatostatin type 2 receptor (SSTR2) radionuclide therapy using β

Indexed as

Copper RadioisotopesHeterocyclic Compounds, 1-RingRadiopharmaceuticalsReceptors, SomatostatinAcetatesAlbuminsAnimalsCell Line, TumorDisease Models, AnimalFemaleHumansMicePheochromocytomaTheranostic NanomedicineTissue Distribution1-(1,3-carboxypropyl)-4,7-carboxymethyl-1,4,7-triazacyclononaneAcetatesAlbuminsCopper-67Copper RadioisotopesHeterocyclic Compounds, 1-RingRadiopharmaceuticalsReceptors, SomatostatinSstr2 protein, mousealbumin binderallograft modelcopper-67dosimetrypheochromocytomaSPECT imaging

Identifiers

PMID39310112
PMCPMC11413788

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.